Combination Chemotherapy in Patients With Zollinger-Ellison Syndrome and Tumors of the Pancreas
Launched by NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES (NIDDK) · Nov 3, 1999
Current as of March 02, 2024
Heretofore morbidity and risk of death in Zollinger-Ellison syndrome were caused by severe ulcer disease. The advent of specific drugs to cure ulcer disease now extends life until metastases from the non-beta-islet cell tumor cause death. The present study proposes to continue to test the effect of combined chemotherapy with streptozotocin, 5-fluorouracil and doxorubicin in biopsy-proven cases of metastatic non-beta-islet cell tumor in patients with Zollinger-Ellison syndrome. We published our initial experience with this protocol in 1988. An objective response was observed in 40% of patients.
- INCLUSION CRITERIA
- Subjects selected for this study will be patients with Zollinger-Ellison syndrome who are being evaluated under the protocol entitled "Diagnostic Evaluation of Patients with Suspected Abnormalities of Gastric Secretion" (80-DK-0123).
- Histologically proven gastrinoma;
- Evidence of metastatic disease or locally invasive tumor by angiography, ultrasound, computerized axial tomography, MRI scan or bone scan;
- Progression of the tumor during the preceding 6 months.
- EXCLUSION CRITERIA
- The following pre-existing conditions will exclude patients from the study:
- Congestive heart failure;
- Proteinuria greater than 1 gram/day;
- Serum creatinine greater than 1.5 mg%;
- Platelet count less than 100,000/mm3;
- White blood count less than 2500/mm3;
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Bethesda, Maryland, United States
All reviews come from applied patients